摘要
目的了解齐拉西酮注射液治疗精神分裂症急性期兴奋、激越的疗效和不良反应。方法将70例精神分裂症急性期患者随机分为研究组(n=35)和对照组(n=35),研究组肌内注射齐拉西酮,10～20 mg/d;对照组肌内注射氟哌啶醇10～30 mg/d。4天为1观察周期,以阳性和阴性症状量表兴奋因子条目(PANSS-EC)减分率为疗效判定标准,不良反应采用副反应量表(TESSS)评分。结果有效率研究组与对照组相比,差异无统计学意义(χ2=0.092,P>0.05),PANSS-EC评分差异无统计学意义。不良反应发生率研究组与对照组比较,差异有统计学意义(χ2=4.88,P<0.01)。结论齐拉西酮注射液治疗精神分裂症急性期兴奋、激越,疗效和氟哌啶醇注射液相当,但不良反应比氟哌啶醇轻。
[Objective]To study the efficacy of ziprasidone injection on excitation and agitation of schizophrenia in the acute phase,and its adverse reactions. [Methods]70 patients with schizophrenia in the acute phase were randomly divided into the study group（35 cases） and the control group（35 cases）.The study group was treated with ziprasidone by intramuscular injection,10～20 mg/d.The control group was given haloperidol by intramuscular injection,10～30 mg/d.Four days was one observation course.The reducing score rate of Positive and Negative Syndrome Scale-Excited Component（PANSS-EC） was used as the judgment standard of efficacy,and Treatment Emergernt Side effect Scale（TESSS） was adopted to evaluate the adverse reactions. [Results]There was no significant difference in effective rate between the study group and the control group（χ2=0.092,P0.05）,and the difference in PANSS-EC was not significant.But there was significant difference in incidence of adverse reactions between the study group and the control group（χ2=4.88,P0.01）. [Conclusion]The ziprasidone injection and haloperidol injection have similar efficacy on excitation and agitation of schizophrenia in the acute phase,and ziprasidone injection has less adverse reactions.
出处
《职业与健康》
CAS
2011年第24期2952-2953,共2页
Occupation and Health
